Primary pigmented nodular adrenocortical disease reveals insulin-like growth factor binding protein-2 regulation by protein kinase A

Growth Hormone and IGF Research

Volumn 17, Issue 2, 2007, Pages 113-121

  Shi, Zonggao ^a   Henwood, Maria J ^a   Bannerman, Peter ^b   Batista, Dalia ^c   Horvath, Anelia ^c   Guttenberg, Marta ^b   Stratakis, Constantine A ^c   Grimberg, Adda ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Adrenocortical cells; cAMP dependent protein kinase (PKA); Insulin like growth factor binding protein (IGFBP) 2; NCI H295R cells; Primary pigmented nodular adrenocortical disease (PPNAD); PRKAR1A gene

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PARAFFIN; RNA; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2;

ADOLESCENT; ADRENAL CORTEX DISEASE; ADRENAL CORTEX TUMOR; ADRENALECTOMY; ADULT; ARTICLE; CARNEY COMPLEX; CELL LINE; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CUSHING SYNDROME; EMBEDDING; ENZYME REGULATION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SIGNAL TRANSDUCTION;

ADRENAL CORTEX NEOPLASMS; CELL LINE; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR II; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 34047172992     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2006.12.004     Document Type: Article

References (47)

1. Shenoy B.V., Carpenter P.C., and Carney J.A. Bilateral primary pigmented nodular adrenocortical disease. Rare cause of the Cushing syndrome. Am. J. Surg. Pathol. 8 (1984) 335-344
2. Lacroix A., and Bourdeau I. Bilateral adrenal Cushing's syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease. Endocrinol. Metab. Clin. North Am. 34 (2005) 441-458 x
3. Stratakis C.A., Kirschner L.S., and Carney J.A. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J. Clin. Endocrinol. Metab. 86 (2001) 4041-4046
4. Stratakis C.A., Carney J.A., Lin J.P., et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J. Clin. Invest. 97 (1996) 699-705
5. Kirschner L.S., Carney J.A., Pack S.D., et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat. Genet. 26 (2000) 89-92
6. Groussin L., Cazabat L., Rene-Corail F., Jullian E., and Bertherat J. Adrenal pathophysiology: lessons from the Carney complex. Horm. Res. 64 (2005) 132-139
7. Sutter J.A., and Grimberg A. Adrenocortical tumors and hyperplasias in childhood-etiology, genetics, clinical presentation and therapy. Pediatr. Endocrinol. Rev. 4 (2006) 366-373
8. Boulle N., Logie A., Gicquel C., Perin L., and Le B.Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 83 (1998) 1713-1720
9. Boulle N., Baudin E., Gicquel C., et al. Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. Eur. J. Endocrinol. 144 (2001) 29-36
10. Logie A., Boulle N., Gaston V., et al. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J. Mol. Endocrinol. 23 (1999) 23-32
11. Logie A., Boudou P., Boccon-Gibod L., et al. Establishment and characterization of a human adrenocortical carcinoma xenograft model. Endocrinology 141 (2000) 3165-3171
12. Rainey W.E., Bird I.M., and Mason J.I. The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Mol. Cell Endocrinol. 100 (1994) 45-50
13. Kirschner L.S., Sandrini F., Monbo J., Lin J.P., Carney J.A., and Stratakis C.A. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the Carney complex. Hum. Mol. Genet. 9 (2000) 3037-3046
14. Stratakis C.A., Carney J.A., Kirschner L.S., et al. Synaptophysin immunoreactivity in primary pigmented nodular adrenocortical disease: neuroendocrine properties of tumors associated with Carney complex. J. Clin. Endocrinol. Metab 84 (1999) 1122-1128
15. Gunther D.F., Bourdeau I., Matyakhina L., et al. Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease or a new entity?. J. Clin. Endocrinol. Metab. 89 (2004) 3173-3182
16. Liu J., Li X.D., Ora A., Heikkila P., Vaheri A., and Voutilainen R. cAMP-dependent protein kinase activation inhibits proliferation and enhances apoptotic effect of tumor necrosis factor-alpha in NCI-H295R adrenocortical cells. J. Mol. Endocrinol. 33 (2004) 511-522
17. Bertherat J., Groussin L., Sandrini F., et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res. 63 (2003) 5308-5319
18. Robinson-White A., Hundley T.R., Shiferaw M., Bertherat J., Sandrini F., and Stratakis C.A. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum. Mol. Genet. 12 (2003) 1475-1484
19. Bossis I., and Stratakis C.A. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology 145 (2004) 5452-5458
20. http://prospector.nci.nih.gov.
21. Zhang X., Odom D.T., Koo S.H., et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. USA 102 (2005) 4459-4464
22. Guan H., Hou S., and Ricciardi R.P. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J. Biol. Chem. 280 (2005) 9957-9962
23. Cazals V., Nabeyrat E., Corroyer S., de K.Y., and Clement A. Role for NF-kappa B in mediating the effects of hyperoxia on IGF-binding protein 2 promoter activity in lung alveolar epithelial cells. Biochim. Biophys. Acta 1448 (1999) 349-362
24. Lambert H.W., Weiss E.R., and Lauder J.M. Activation of 5-HT receptors that stimulate the adenylyl cyclase pathway positively regulates IGF-I in cultured craniofacial mesenchymal cells. Dev. Neurosci. 23 (2001) 70-77
25. Thomas M.J., Umayahara Y., Shu H., Centrella M., Rotwein P., and McCarthy T.L. Identification of the cAMP response element that controls transcriptional activation of the insulin-like growth factor-I gene by prostaglandin E2 in osteoblasts. J. Biol. Chem. 271 (1996) 21835-21841
26. Suwanichkul A., DePaolis L.A., Lee P.D., and Powell D.R. Identification of a promoter element which participates in cAMP-stimulated expression of human insulin-like growth factor-binding protein-1. J. Biol. Chem. 268 (1993) 9730-9736
27. Chen Y., Shu H., Ji C., et al. Insulin-like growth factor binding proteins localize to discrete cell culture compartments in periosteal and osteoblast cultures from fetal rat bone. J. Cell Biochem. 71 (1998) 351-362
28. Price W.A. PDGF-BB regulates IGF-mediated IGFBP-4 proteolysis in fetal lung fibroblasts. Exp. Lung Res. 27 (2001) 655-674
29. Sirotkin A.V., and Makarevich A.V. Growth hormone can regulate functions of porcine ovarian granulosa cells through the cAMP/protein kinase A system. Anim. Reprod. Sci. 70 (2002) 111-126
30. Ongeri E.M., Verderame M.F., and Hammond J.M. Follicle-stimulating hormone induction of ovarian insulin-like growth factor-binding protein-3 transcription requires a TATA box-binding protein and the protein kinase A and phosphatidylinositol-3 kinase pathways. Mol. Endocrinol. 19 (2005) 1837-1848
31. Hammer G.D., Parker K.L., and Schimmer B.P. Minireview: transcriptional regulation of adrenocortical development. Endocrinology 146 (2005) 1018-1024
32. Carrick F.E., Hinds M.G., McNeil K.A., Wallace J.C., Forbes B.E., and Norton R.S. Interaction of insulin-like growth factor (IGF)-I and -II with IGF binding protein-2: mapping the binding surfaces by nuclear magnetic resonance. J. Mol. Endocrinol. 34 (2005) 685-698
33. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol. Ther. 2 (2003) 630-635
34. Grimberg A., and Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell Physiol. 183 (2000) 1-9
35. Hoeflich A., Reisinger R., Lahm H., et al. Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?. Cancer Res. 61 (2001) 8601-8610
36. Besnard V., Corroyer S., Trugnan G., et al. Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells. Biochim. Biophys. Acta 1538 (2001) 47-58
37. Hoeflich A., Reisinger R., Schuett B.S., et al. Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem. Biophys. Res. Commun. 324 (2004) 705-710
38. Hoeflich A., Fettscher O., Lahm H., et al. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res. 60 (2000) 834-838
39. Chatterjee S., Park E.S., and Soloff M.S. Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2. Int. J. Urol. 11 (2004) 876-884
40. Lee E.J., Mircean C., Shmulevich I., et al. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol. Cancer 4 (2005) 7
41. Miyake H., Hara I., Yamanaka K., Muramaki M., Gleave M., and Eto H. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol. Rep. 13 (2005) 341-345
42. Wang H., Wang H., Shen W., et al. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res. 63 (2003) 4315-4321
43. Hoeflich A., Fettscher O., Preta G., et al. Increased activity of catalase in tumor cells overexpressing IGFBP-2. Horm. Metab. Res. 35 (2003) 816-821
44. Pereira J.J., Meyer T., Docherty S.E., et al. Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res. 64 (2004) 977-984
45. Schutt B.S., Langkamp M., Rauschnabel U., Ranke M.B., and Elmlinger M.W. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J. Mol. Endocrinol. 32 (2004) 859-868
46. Russo V.C., Schutt B.S., Andaloro E., et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146 (2005) 4445-4455
47. Song S.W., Fuller G.N., Khan A., et al. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc. Natl. Acad. Sci. USA 100 (2003) 13970-13975